<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593317</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0038</org_study_id>
    <nct_id>NCT03593317</nct_id>
  </id_info>
  <brief_title>Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD</brief_title>
  <acronym>BRAVE</acronym>
  <official_title>Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD: a Double-blind Multicentre Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by&#xD;
      the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right&#xD;
      ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular&#xD;
      arrhythmia.&#xD;
&#xD;
      Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia.&#xD;
      Thus, there is no validated treatment that will prevent the deterioration of the RV function&#xD;
      in patients with ARVD.&#xD;
&#xD;
      The investigator's hypothesis is that the use of anti-fibrotic medications will prevent or at&#xD;
      least reduce the deterioration of the RV function. The aim of this project is to evaluate the&#xD;
      effect of spironolactone, a Potassium-sparing diuretic on ventricular myocardial remodeling&#xD;
      and on arrhythmia burden in patients with ARVD.&#xD;
&#xD;
      The trial is a double-blind parallel multicenter prospective randomized phase II drug study.&#xD;
      Patients will be randomized in the two groups: spironolactone or placebo. 19 centers in&#xD;
      France will enroll the 120 patients (60 per group). Patients will be followed up every 6&#xD;
      months for 3 years. A decrease in right and/or left ventricular deterioration and in&#xD;
      arrhythmia burden are expected in ARVD patients treated with spironolactone. This reduction&#xD;
      will improve the quality of life of patients and will reduce the number of hospitalizations&#xD;
      and the risk of terminal heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricle volume measured by MRI</measure>
    <time_frame>at year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of ventricular extrasystoles on 24h-Holter ECG</measure>
    <time_frame>at year 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>left ventricle measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricle measured by echocardiography</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aneurism measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aneurism measured by echocardiography</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyskinesia measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyskinesia measured echocardiography</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of QRS width (50mm/s) on ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Morphologic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventricular extrasystoles on 24h Holter ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sustained ventricular tachycardia on 24h Holter ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of PR interval duration on ECG</measure>
    <time_frame>at 6 month</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late potentials measured with high amplification ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventricular extrasystoles by stress test</measure>
    <time_frame>at year 3</time_frame>
    <description>Rhythmic criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of functional symptoms by recording adverse events</measure>
    <time_frame>at year 3</time_frame>
    <description>Functional criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions owing to clinical deterioration</measure>
    <time_frame>at year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of telediastolic right ventricle volume measured by MRI</measure>
    <time_frame>at year 3</time_frame>
    <description>according to the genotype of desmosome genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arrhythmia burden measured by 24h Holter ECG</measure>
    <time_frame>at year 3</time_frame>
    <description>according to the genotype of desmosome genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of MMP9 (Matrix metallopeptidase 9)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of TIMP1 (Tissue Inhibitory MetalloProtease 1)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of TIMP2 (Tissue Inhibitory MetalloProtease 2)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of IL6 (Interleukin 6)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of IL8 (Interleukin 8)</measure>
    <time_frame>at year 3</time_frame>
    <description>Quantification of inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Arrhythmogenic Right Ventricular Dysplasia</condition>
  <arm_group>
    <arm_group_label>Spironolactone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 36 months.</description>
    <arm_group_label>Spironolactone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 36 months.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18years old&#xD;
&#xD;
          -  Diagnosis of ARVD based on Task Force criteria. Two major criteria: 1 morphologic and&#xD;
             one rhythmic or 1 major and 2 minor criteria established by the European Society of&#xD;
             Cardiology/International Society and Federation of Cardiology.&#xD;
&#xD;
          -  Increased right ventricular volume (&gt; 100ml/m² female; &gt; 110ml/m² male)&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction &gt;40%&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  No health insurance.&#xD;
&#xD;
          -  MRI contraindication (claustrophobia, implantable defibrillator).&#xD;
&#xD;
          -  Right heart failure patient (RV volume&gt;150ml)&#xD;
&#xD;
          -  Spironolactone contraindication (hypotension, renal failure).&#xD;
&#xD;
          -  Normal right ventricular volume&#xD;
&#xD;
          -  Heart transplantation&#xD;
&#xD;
          -  Swallowing disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Chevalier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elodie Morel, PhD</last_name>
    <phone>4 72 35 73 81</phone>
    <phone_ext>+33</phone_ext>
    <email>elodie.morel01@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Chevalier, MD, PhD</last_name>
    <phone>4 72 35 70 27</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.chevalier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Cardiologique Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Chevalier</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Right ventricle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

